Vanda Pharmaceuticals | VNDA - Acreedores Comerciales





Acreedores Comerciales Cambio Fecha
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
Akebia Therapeutics USD 21.18M 11.1M 2025-12
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
Anika Therapeutics USD 6.34M 298K 2026-03
Arrowhead Research USD 32.94M 15.26M 2025-12
AstraZeneca USD 22.51B 2.78B 2026-03
Bristol-Myers Squibb USD 4.23B 659M 2026-03
Eli Lilly USD 5.03B 350M 2026-03
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Heron Therapeutics USD 8.99M 3.02M 2025-12
Insmed USD 79.91M 316K 2025-12
J&J USD 10.46B 1.53B 2026-03
Lexicon Pharmaceuticals USD 3.08M 714K 2025-12
Ligand Pharmaceuticals USD 3.24M 24.52M 2025-12
Merck USD 3.86B 541M 2026-03
Minerva Neurosciences USD 640K 305K 2025-12
Moderna USD 161M 156M 2026-03
Novartis USD 4.46B 99M 2025-12
Pfizer USD 4.51B 734M 2026-03
PTC Therapeutics USD 45.49M 8.87M 2025-12
Puma Biotechnology USD 6.39M 962K 2025-09
Sangamo BioSciences USD 10.74M 7.46M 2025-06
Sanofi EUR 22.71B 219M 2026-03
Takeda JPY 467.59B 28.61B 2025-12
Teva Pharmaceutical Industries USD 2.6B 65M 2026-03
Ultragenyx Pharmaceutical USD 31M 9.57M 2025-12
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Veracyte USD 4.59M 916K 2025-12